Abstracts Archive - Page 362 of 2607 - ACR Meeting Abstracts

Abstract Number: 0850 • ACR Convergence 2024
Assessment of Correlation Between Composite Ultrasonographic Index (ECODAS) and Disease Activity Score 28 in Patients with Rheumatoid Arthritis
Komal Verma Saluja¹, Harshvardhan Khokhar², Amit Sharma³ and Saurabh Chittora², ¹Government Medical college Kota, Kota, Rajasthan, India, ²Government Medical college Kota, Kota, India, ³Fortis hospital Jaipur, Jaipur, India
Background/Purpose: Conventional Disease Activity Score 28 has variable sensitivity, subjectivity, inherent bias due to certain variables such as more weightage to joint tenderness and overestimation…
Abstract Number: 0879 • ACR Convergence 2024
A Novel, Oral, Allosteric Inhibitor of Tyrosine Kinase 2 (TYK2) Demonstrates In Vitro Potency, Selectivity, and In Vivo Efficacy in Mouse Models of Psoriasis
Razika Hussein¹, Pamela Tsuruda¹, Shahab Mortezaei¹, Nicky Ferdyan¹, Christopher Wegerski², Karthik Srinivasan¹, Gavin Hirst¹ and Neelufar Mozaffarian¹, ¹Atomwise Inc., San Francisco, ²Atomwise Inc., San Francisco, CA
Background/Purpose: Tyrosine kinase 2 (TYK2), a member of the Janus kinase (JAK) family, plays a key role in several inflammatory diseases. Orthosteric, small molecule inhibitors…
Abstract Number: 0648 • ACR Convergence 2024
Prevalence of Pulmonary Complications Among Patients with Systemic Lupus Erythematosus (SLE): A Systematic Review and Meta-analysis
Athanasios Vassilopoulos¹, Stephanos Vassilopoulos², Jasneet Singh², Ingrid Lazaridou², Markos Kalligeros², Eleftherios Mylonakis³ and Anthony M. Reginato⁴, ¹Warren Alpert Medical School of Brown University, Providence, RI, ²Division of Internal Medicine, Warren Alpert Medical School of Brown University, Rhode Island Hospital, Providence, Rhode Island, Providence, RI, ³Department of Medicine, Houston Methodist Hospital, Houston, ⁴Brown University, Providence, RI
Background/Purpose: Pleuritis remains the most common pulmonary manifestation in patients with SLE. The prevalence of other less common complications of SLE such as: interstitial lung…
Abstract Number: 0884 • ACR Convergence 2024
Genetic Architecture Divergence in Sjögren’s Disease Subphenotypes and Populations: Genome-wide Association Study of Ro/SSA+ and Ro/SSA- Cases in European Populations
Marcin Radziszewski¹, Astrid Rasmussen², Bhuwan Khatri², Kandice Tessneer², Elena Pontarini³, Michele Bombardieri⁴, Maureen Rischmueller⁵, Marie Wahren-Herlenius⁶, Marika Kvarnström⁶, Torsten Witte⁷, Hendrika Bootsma⁸, Gwenny Verstappen⁹, Frans Kroese⁹, Arjan Vissink¹⁰, Sarah Pringle⁹, Athanasios Tzioufas¹¹, Clio Mavragani¹², Alan Baer¹³, Marta Alarcon-Riquelme¹⁴, Javier Martin¹⁵, Xavier Mariette¹⁶, Gaetane Nocturne¹⁶, Jacques-Olivier Pers¹⁷, Jacques-Eric Gottenberg¹⁸, Wan-Fai Ng¹⁹, Caroline Shiboski²⁰, Kim Taylor²¹, Lindsey Criswell²², Blake M. Warner²³, A. Darise Farris², Judith James², Robert Hal Scofield², Joel Guthridge², Daniel Wallace²⁴, Swamy Venuturupalli²⁵, Michael Brennan²⁶, Juliana Imgenberg-Kreuz²⁷, Lars Rönnblom²⁷, Eva Baecklund²⁷, Maija-Leena Eloranta²⁷, Lara Aqrawi²⁷, Øyvind Palm²⁸, Johan Brun²⁹, Daniel Hammenfors²⁹, Malin Jonsson²⁹, Silke Appel²⁹, Sara Magnusson Bucher³⁰, Helena Forsblad-d'Elia³¹, Thomas Mandl³² and Christopher Lessard², ¹University of Oklahoma Health Sciences Center, Oklahoma City, OK, ²Oklahoma Medical Research Foundation, Oklahoma City, OK, ³Queen Mary University of London, London, United Kingdom, ⁴Centre for Experimental Medicine and Rheumatology, The William Harvey Research Institute, Queen Mary University of London, London, United Kingdom, ⁵RheumatologySA, Adelaide, Australia, ⁶Karolinska Institutet, Stockholm, Sweden, ⁷Dept of Immunology and Rheumatology, Hannover, Germany, ⁸Department of Rheumatology and Clinical Immunology, University of Groningen, University Medical Center Groningen, Groningen, Groningen, Netherlands, ⁹University Medical Center Groningen, Groningen, Netherlands, ¹⁰University Medical Center Groningen, Leek, Netherlands, ¹¹LAIKO HOSPITAL, Athens, Greece, ¹²National and Kapodistrian University of Athens, Athens, Greece, ¹³Johns Hopkins University School of Medicine, Baltimore, MD, ¹⁴Fundación Progreso y Salud, Andalusian Government, Granada, Spain, ¹⁵Instituto de Parasitología y Biomedicina ‘López-Neyra’, CSIC, PTS Granada, Spain, Granada, Spain, ¹⁶Service de Rhumatologie, Hôpital Bicêtre, AP-HP, Le Kremlin Bicetre, France, ¹⁷University of Brest, Brest, France, ¹⁸Rheumatology Department, Strasbourg University Hospital,, Strasbourg, France, ¹⁹Institute of Cellular Medicine, Newcastle University, Gateshead, United Kingdom, ²⁰University of California San Francisco, San Francisco, CA, ²¹University of California, San Francisco, CA, ²²Genomics of Autoimmune Rheumatic Disease Section, National Human Genome Research Institute, National Institutes of Health, Bethesda, MD, Bethesda, MD, ²³National Institutes of Health, Bethesda, MD, ²⁴Cedars Sinai Medical Center, Studio City, CA, ²⁵Attune Health, Beverly Hills, CA, ²⁶Atrium Health Carolinas Medical Center, Charlotte, NC, ²⁷Uppsala University, Uppsala, Sweden, ²⁸University of Oslo, Oslo, Norway, ²⁹University of Bergen, Bergen, Norway, ³⁰Universitetssjukhuset, Orebro, Sweden, ³¹University of Gothenburg, Gothenburg, Sweden, ³²Lund University, Malmö, Sweden
Background/Purpose: Sjögren's disease (SjD) is a complex systemic autoimmune disease with 22 genome-wide significant (GWS) risk loci [1]. Historically, genomic research has focused on populations…
Abstract Number: 0415 • ACR Convergence 2024
Prevalence and Risk Factors of Low Bone Mineral Density in Children with Juvenile Idiopathic Arthritis
narendra bagri, Sushain Kalsotra, vandana jain, Manisha Jana, Maroof Ahmed Khan, Yashdeep Gupta and Sumit Kumar Das, All India Institute of Medical Sciences, New Delhi, Delhi, India
Background/Purpose: Juvenile idiopathic arthritis (JIA) is the most common chronic rheumatological disease in children less than 16 years of age. Various factors have been suggested…
Abstract Number: 0434 • ACR Convergence 2024
Pregnancy Outcomes of Biosimilars and Non-TNF Inhibitor Biologic Disease-Modifying Antirheumatic Drugs: A Scoping Review
Vienna Cheng¹, Neda Amiri², Vicki Cheng¹, Ursula Ellis³, Jacquelyn J. Cragg¹, Mark Harrison¹ and Mary A. De Vera¹, ¹University of British Columbia, Faculty of Pharmaceutical Sciences, Vancouver, BC, Canada, ²University of British Columbia, Faculty of Medicine, Vancouver, BC, Canada, ³University of British Columbia, Woodward Library, Vancouver, BC, Canada
Background/Purpose: Biosimilar and biologic (b) DMARDs have revolutionized rheumatic disease management in the recent decades. As these drugs become introduced, it is important to understand…
Abstract Number: 0665 • ACR Convergence 2024
Belimumab Induces Early and Sustained Resolution of Lupus Thrombocytopenia and Lupus Arthritis
Nicolai Leuchten¹, Ioannis Parodis², Ralph Brinks³ and Martin Aringer¹, ¹University Medical Center and Faculty of Medicine TU Dresden, Dresden, Germany, ²Karolinska Institutet, Karolinska University Hospital; Örebro University, Solna, Sweden, ³University Witten/Herdecke, Witten, Germany
Background/Purpose: Belimumab has well-established efficacy in improving overall SLE disease activity and in preventing flares and organ damage. In clinical routine, however, the primary goal…
Abstract Number: 0799 • ACR Convergence 2024
Peripheral Biomarker Signatures and a Genetic Risk Score Improve the Identification of RA-ILD Beyond Clinical Risk Factors
Austin Wheeler¹, Thomas Riley², Joshua Baker³, Yangyuna Yang¹, Punyasha Roul⁴, Katherine Wysham⁵, grant Cannon⁶, Gary Kunkel⁷, Gail Kerr⁸, Dana Ascherman⁹, Paul Monach¹⁰, Andreas Reimold¹¹, Jill Poole¹, Tony Merriman¹², Ted Mikuls¹ and Bryant England¹, ¹University of Nebraska Medical Center, Omaha, NE, ²Hopsital of the University of Pennsylvania, Philadelphia, PA, ³University of Pennsylvania, Philadelphia, PA, ⁴UNMC, Omaha, NE, ⁵VA PUGET SOUND/UNIVERSITY OF WASHINGTON, Seattle, WA, ⁶University of Utah and Salt Lake City VA, Salt Lake City, UT, ⁷University of Utah and George E Wahlen VAMC, Salt Lake City, UT, ⁸Washington DC VAMC/Georgetown and Howard Universities, Washington, DC, ⁹Division of Rheumatology and Clinical Immunology, University of Pittsburgh Medical Center, Pittsburgh, PA, ¹⁰VA Boston Healthcare System, Boston, MA, ¹¹Dallas VA Medical Center, Dallas, TX, ¹²University of Alabama at Birmingham, Homewood, AL
Background/Purpose: Rheumatoid arthritis-associated interstitial lung disease (RA-ILD) is an extra-articular manifestation of RA that causes substantial morbidity and mortality. Despite the paucity of known risk…
Abstract Number: 0421 • ACR Convergence 2024
The Effect of Biologic Treatment for Psoriatic Arthritis and Axial Spondyloarthritis on Semen Parameters – a Longitudinal Study
Katya Meridor¹, Shimi Barda², sara Pel³, sharon Nevo², Julia Berman², daphna paran⁴, Ori Elkayam⁵ and Ari Polachek⁶, ¹Tel Aviv Medical Center, Kfar Saba, Israel, ²Tel-Aviv Medical Center, Tel-Aviv, Israel, ³Tel-Aviv Medical Center, Petah-Tikva, Israel, ⁴Tel-Aviv Medical Center, EVEN-YEHUDA, Israel, ⁵Tel Aviv Sourasky Medical Center, Tel Aviv, Israel, ⁶Tel-Aviv Medical Center, Tel-Aviv, Israel, Petah-Tikva, Israel
Background/Purpose: Psoriatic arthritis (PsA) and axial spondyloarthritis (AxSpA) are commonly diagnosed in young males in their reproductive years. However, only a few studies have investigated…
Abstract Number: 0859 • ACR Convergence 2024
Incidence of Aortic Aneurysm, Dissection, or Rupture Among Patients with Polymyalgia Rheumatica and Giant Cell Arteritis
Kylie Carlson¹, Mahmut Kaymakci², Sebastian E. Sattui³ and Michael Putman⁴, ¹Medical College of Wisconsin, Milwaukee, WI, ²Mayo Clinic, Rochester, MN, ³University of Pittsburgh, Pittsburgh, PA, ⁴The Medical College of Wisconsin, Milwaukee, WI
Background/Purpose: Patients with polymyalgia rheumatica (PMR) may develop overt giant cell arteritis (GCA), but “subclinical” large vessel inflammation has also been reported in patients with…
Abstract Number: 0878 • ACR Convergence 2024
YY1 a Potential Modulator of IL17/IL23 Axis in Psoriasis Disease
vinod kumar, Tammana Sharma, Rahul Mahajan, Tarun Narang, Sunil Dogra and Sanjeev handa, PGIMER, Chandigarh, Chandigarh, India
Background/Purpose: Psoriasis is an inflammatory skin disease that progresses and worsens if left unattended. IL17 plays a pivotal role as a pathogenic trigger. Despite Th17…
Abstract Number: 0886 • ACR Convergence 2024
A Longitudinal Cohort Study Uncovers Plasma Protein Biomarkers Predating Clinical Onset and Treatment Response of Rheumatoid Arthritis
Chenxi Zhu¹, Siyu He², Yi Liu³, Rui Sun¹ and Yi Zhao⁴, ¹Department of Rheumatology and Immunology, West China Hospital,Sichuan University, Chengdu, Sichuan, China, chengdu, China (People's Republic), ²West China Hospital Sichuan University, chengdu, China (People's Republic), ³Department of Rheumatology and Immunology, West China Hospital,Sichuan University, Chengdu, Sichuan, China, chengdu, ⁴Department of Rheumatology and Immunology, West China Hospital,Sichuan University, Chengdu, Sichuan, China, Sichuan, China (People's Republic)
Background/Purpose: Rheumatoid arthritis (RA) is a complex systemic inflammatory autoimmune disease with a high incidence, primarily affecting the joints. However, it currently lacks definitive biomarkers…
Abstract Number: 0788 • ACR Convergence 2024
Long-term Effectiveness of a Lifestyle Intervention for Osteoarthritis: Two-year Follow-up After the “Plants for Joints” Randomized Clinical Trial
Carlijn Wagenaar¹, Wendy Walrabenstein², Marike van der Leeden², Martijn Gerritsen¹, Jos Twisk³, Martin van der Esch², Henriët van Middendorp⁴, Peter Weijs⁵ and Dirkjan van Schaardenburg⁶, ¹Reade Rheumatology Center, Amsterdam, Netherlands, ²Reade Center for Rheumatology and Rehabilitation, Amsterdam, Netherlands, ³Amsterdam UMC location Vrije Universiteit Amsterdam, Amsterdam, Netherlands, ⁴Leiden University, Leiden, Netherlands, ⁵Amsterdam University of Applied Sciences, Amsterdam, Netherlands, ⁶Amsterdam UMC, Amsterdam, Netherlands
Background/Purpose: The 16-week Plants for Joints (PFJ) multidisciplinary lifestyle Intervention, based on a whole-food plant-based diet, physical activity, and stress management, significantly reduced The Western…
Abstract Number: 0703 • ACR Convergence 2024
Preliminary Results from the RECONNOITER Trial, a Phase 2 Study of AISA 021 in the Treatment of Secondary Raynaud’s, Primarily Due to Systemic Sclerosis
Andrew Sternlicht¹, Michael Shanahan², Erin Morton², Meredith Todd³, Ivana Hunt², Zoey Reed², amanda weragoda⁴, Lashika Weerakoon² and Elizabeth Briggs², ¹Tufts University Medical Center and Aisa Pharma, Inc., Boston, MA, ²Flinders Medical Centre, Adelaide, Australia, ³Aisa Pharma Pty Ltd., East Lindfield, New South Wales, Australia, ⁴F, Adelaide, Australia
Background/Purpose: While 95% of Systemic Sclerosis (SSc) patients have Raynaud’s phenomenon(RP) and many patients rate it as the most bothersome and severe symptom of their…
Abstract Number: 0443 • ACR Convergence 2024
Significance of anti-Ro52 Antibody in Pregnancy Complicated with Anti-SS-A Antibody Positive Rheumatic Disease Patients
Hiromi Shimada¹, Rina Mino², taichi miyagi³, Yusuke Ushio⁴, Koichi Sugihara⁵, Mao Mizusaki², Hayamasa yamaguchi², Naoto Manabe², Shusaku Nakashima¹ and Hiroaki Dobashi¹, ¹Department of Internal Medicine, Division of Hematology, Rheumatology and Respiratory Medicine, Faculty of Medicine, Kagawa University, Kagawa, Japan, ²Department of Internal Medicine, Division of Hematology, Rheumatology and Respiratory Medicine, Faculty of Medicine, Kagawa University, Miki-cho, Kita-gun, Japan, ³Department of Internal Medicine, Division of Hematology, Rheumatology and Respiratory Medicine, Faculty of Medicine, Kagawa University, kidagun, Japan, ⁴Department of Internal Medicine, Division of Hematology, Rheumatology and Respiratory Medicine, Faculty of Medicine, Kagawa University, Miki, Kita District, Kagawa, Japan, ⁵Department of Internal Medicine, Division of Hematology, Rheumatology and Respiratory Medicine, Faculty of Medicine, Kagawa University, Miki-cho, Kita-gun, Kagawa Prefecture, Japan
Background/Purpose: Anti-SS-A antibodies are associated with neonatal lupus erythematosus and congenital heart block (CHB). Ro/SS-A autoantigen is comprised of 52kDa Ro (Ro52) and 60kDa Ro…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].